Crinetics Pharmaceuticals, Inc. — Earnings Quality Grade F
CRNX · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
Insufficient data
Revenue grew 640.7% but CFFO declined -64.2%
Expense Quality
Insufficient data
CapEx growth 49.9% vs revenue 640.7%. Normal
SG&A/Gross Profit = 2890.2%, exceeds 70%
Gross margin swung -14.0pp (100.0% → 86.0%)
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF is negative ($-0.4B)
Accruals ratio = -7.8%. Low accruals
Cash $1.0B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -0.1x. Healthy
Other assets 537.3% vs revenue 640.7%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
No goodwill
Manipulation Score
Calculation error: float division by zero
Portfolio monitoring
Monitor CRNX continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25